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Hormones and bone
Francisco Bandeira1, Marise Lazaretti-Castro2, John P. Bilezikian3
During childhood, skeletal growth velocity and growth plate activities are large-ly dependent on growth hormone, IGF-1 and thyroid hormone, along with the 
calcium-regulating hormones, parathyroid hormone and vitamin D. Altogether, the hor-
monal influence on optimal skeletal growth and peak bone mass is enormously important. 
Sex hormones have considerable influence not only on bone density, but also on 
bone quality. Data from studies of long bone geometry have shown that both testos-
terone and estradiol influence the cross-sectional area. Testosterone acts mainly on the 
periosteal surface while estradiol appears to influence bone growth on the endosteal 
surface (1). The influence of estrogen on the male skeleton has been shown in the con-
text of growth and epiphyseal maturation through studies of men with an inability to 
produce estrogen because of aromatase deficiency. In addition, men with genetic pre-
disposition to have greater aromatase activity through polymorphisms of the CYP19 
gene have higher estrogen levels and less age-related bone loss (2-3). Moreover, cross-
sectional studies have emphasized the importance of estrogen levels in maintaining 
male skeletal mass (4). 
Parathyroid hormone (PTH) is unique in its actions on bone strength as it may 
have profoundly negative or positive effects, depending on the manner in which it is 
secreted or administered. From a therapeutic point of view, intermittent, low dose ad-
ministration of PTH is associated with important anabolic effects on the skeleton (5) 
that have been demonstrated in postmenopausal women and in men (6). In primary 
hyperparathyroidism, on the other hand, the chronically high levels of PTH are as-
sociated with a proclivity for bone loss at the distal 1/3 radius, a site that is comprised 
mainly of cortical bone (7,8). Marked improvements in bone mass are seen following 
successful parathyroidectomy in severe primary hyperparathyroidism in a state of hun-
gry bones with hypocalcemia and secondary hyperparathyroidism (9). Improvements 
are also seen in subjects whose primary hyperparathyroidism is characterized primarily 
by densitometric and mild biochemical abnormalities (10). Vitamin D is becoming 
widely recognized as a pivotally important calcium regulating-hormone. Suboptimal 
serum concentrations of 25-hydroxivitamin D have been found in various populations 
worldwide, including those in countries with an abundance of sunlight. These ob-
servations challenge previous notions that sunny climates are associated with normal 
vitamin D levels (11,12). The epidemic of vitamin D deficiency has led to recognition 
that it is involved in many important non-skeleton systems that govern functions of 
muscle, cognition, vision, heart, immunity, insulin sensitivity and cancer risk (12-14). 
Obesity is becoming the center of attention in view of adipocyte hormonal products 
that have important skeletal properties (15). In this regard, controversial issues related 
to hormones and bone strength arise, and some data suggest that the type of body fat 
distribution whether central or peripheral may have different effects on bone metabolism 
related to the degree of inflammation, insulin resistance and adipocyte hormone secre-
tion. Although very high insulin levels present in some rare insulin-resistant states (16) 
may be anabolic to bone, data have emerged that leptin and insulin resistance may nega-
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tively influence BMD (Bone Mineral Density) in obese 
patients at the time of adolescent bone accrual (17).
In this special issue of the Brazilian Archives of En-
docrinology (ABE&M) through the Brazilian Society for 
Endocrinology and Metabolism, these and other issues 
are covered. We would like to express our gratitude to 
all the contributors to this supplement, and very much 
hope that it will offer you an opportunity to update your 
knowledge in this fascinating and fast-moving field.
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